A comparative evaluation of the efficacy and safety of Latanoprost-Optic and Xalatan used as monotherapy and combined with Dorzolamide-Optic for primary open-angle glaucoma under clinical practice conditions

The number of ophthalmic antihypertensive drugs available in Russia is steadily increasing, which complicates the choice to be made by ophthalmologist practitioners. Purpose: to compare the efficacy and safety of the domestically produced drug Latanoprost-Optic with the original drug Xalatan used as monotherapy or combined with the domestic drug Dorzolamide-Optic in patients with primary open-angle glaucoma (POAG). Material and methods. 116 completed cases of patients aged 69.3 ± 5.7 with newly diagnosed POAG were retrospectively analyzed, whereby we assessed the efficacy, safety and tolerability of monotherapy with Latanoprost-Optic or Xalatan and their combinations with Dorzolamide-Optic. Results. Latanoprost-Optic efficacy is no worse than that of Xalatan as it reduces intraocular pressure (IOP) by 33.8%, and has a comparable safety and tolerability profile. More than 72% of patients rate the tolerability of treatment with LatanoprostOptic as very good or good. An additional hypotensive effect of Dorzolamide-Optic added to latanoprost is 2.6–2.8 mm Hg, or 13.2–14.4% and involves no significant effect on the safety profile and tolerability of therapy. Conclusion. Latanoprost-Optic can be considered as a more affordable alternative to the original drug. If the target IOP values cannot be achieved by latanoprost alone, its combination with DorzolamideOptic is recommended, especially for patients with chronic diseases of the respiratory system and the cardiovascular system.

1. Quigley H.A. 21st century glaucoma care. Eye (Lond). 2019; 33 (2): 254–60. doi: 10.1038/s41433-018-0227-8

2. Tham Y.C., Li X., Wong T.Y., et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 2081–90. doi: 10.1016/j. ophtha.2014.05.013

3. Di Stefano A.F. VISION 2020: the right to sight. A global initiative for the elimination of avoidable blindness. Optometry. 2001; 72 (10): 619–22.

4. Lichter P.R., Musch D.C., Gillespie B.W., et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108 (11): 1943–53. doi: 10.1016/s0161-6420(01)00873-9

5. Astakhov Yu.S., Sokolov V.O., Morozova N.V., Novikov D.P. The evaluation of Glaumax pressure-lowering effect. Ophthalmology journal. 2013; 6 (3): 75–9 (in Russian). doi: 10.17816/OV2013375-79

6. Astakhov Y.S., Nechiporenko P.A. Prostaglandin analogues: past, present, and future. Ophthalmology journal. 2017. 10 (1): 40–52 (in Russian). doi: 10.17816/OV10140-52

7. Kuroedov A.V. Prospects of combined antiglaucoma drugs usage (literary review). RMZH. Klinicheskaya oftal’mologija. 2007; 8 (4): 176–80 (in Russian).

8. Coakes R.L., Brubaker R.S. The mechanism of timolol in lowering intraocular pressure. Arch Ophthalmol. 1978; 96 (11): 2045–8. doi: 10.1001/ archopht.1978.03910060433007

9. Stewart W.C., Garrison P.M. Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. Arch. Intern. Med. 1998; 158 (3): 221–6. doi: 10.1001/ archinte.158.3.221

10. Erichev V.P., Makarova A.S. Compatibility of systemic drugs and local antihypertensive therapy in patients with primary open-angle glaucoma (analytical review). National journal glaucoma. 2019; 18 (2): 93–101 (in Russian). https://doi.org/10.25700/NJG.2019.02.10

11. O'Connor D.J., Martone J.F., Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am. J. Ophthalmol. 2002; 133 (6): 836–7. doi: 10.1016/s0002-9394(02)01418-6

12. Petrov S.Yu., Kalinina O.M., Yakubova L.V., et al. Initial hypotensive therapy of primary glaucoma with the domestic latanoprost generic: efficacy and safety. Russian ophthalmological journal. 2021; 14 (4): 7–14 (in Russian). doi.: 10.21516/2072-0076-2021-14-4-supplement-7-14

13. Schiffman R.M., Christianson M.D., Jacobsen G., Hirsch J.D., Reis B.L. Reliability and validity of the Ocular Surface Disease Index. Arch. Ophthalmol. 2000; 118 (5): 615–21. doi: 10.1001/archopht.118.5.615

14. Nelson P., Aspinall P., Papasulitis O., Worton B., O'Brien K. Quality of life in glaucoma and its relationship with visual function. Glaucoma. 2003; 12 (2): 139–50 (in Russian).

15. Primary open-angle glaucoma. Clinical guidelines (in Russian). Available at: http://avo-portal.ru/doc/fkr/approved/item/246-glaukoma-otkrytougolnaya (Accessed 25 Jan. 2023).

16. Stjernschantz J., Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr. Opin. Ophthalmol. 1996; 7 (2): 11–7. doi: 10.1097/00055735-199604000-00003

17. Walters T.R., DuBiner H.B., Carpenter S.P., et al. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv. Ophthalmol. 2004; 49 (1): 26–35. doi: 10.1016/j.survophthal.2003.12.017

18. Zhang W.Y., Po A.L., Dua H.S., Azuara-Blanco A. Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of patients with open-angle glaucoma or ocular hypertension. Br. J. Ophthalmol, 2001; 85 (8): 983–90. doi: 10.1136/bjo.85.8.983

19. Hejkal T.W., Gamras C.B. Prostaglandin analogs in the treatment of glaucoma. Semin. Ophthalmol. 1999; 14 (3): 114–23. doi: 10.3109/08820539909061464

20. Watson P.G. Latanoprost. Two years’ experience of its use in the United Kingdom. Ophthalmology. 1998; 105 (1): 82–7. doi: 10.1016/s0161- 6420(98)91372-0

21. Alm A., Wideng rd I. Latanoprost experience of 2-year treatment in Scandinavia. Acta Ophthalmol. Scand. 2000; 78 (1): 71–6. doi: 10.1034/j.1600- 0420.2000.078001071.x

22. Nelson P., Aspinall P., Papasouliotis O., Worton B., O'Brien C. Quality of life in glaucoma and its relationship with visual function. J. Glaucoma. 2003; 12 (2): 139–50. doi: 10.1097/00061198-200304000-00009

23. Magacho L., Lima F.E., Nery A.C., et al. About quality of life in glaucoma patients. Ophthalmic Epidemiol. 2004; 11 (4): 263–70. doi: 10.1080/09286580490515251

24. O'Connor D.J., Martone J.F., Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am. J. Ophthalmol. 2002; 133 (6): 836–7. doi: 10.1016/s0002-9394(02)01418-6